

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.  
 18467

In Re Application of: Lloyd S. Gray, et al.

Application No. 10/589,216	Filing Date August 11, 2006	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	--------------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title:

**INHIBITING CAV3 ISOFORMS AND THE  $\delta$ 25B SPLICE VARIANTS FOR THE  
 DIAGNOSIS AND TREATMENT OF CANCER**
**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.  
☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP  
 as described below.  
     ☐ Charge the amount of \_\_\_\_\_  
     ☒ Credit any overpayment.  
     ☒ Charge any additional fee required.  
☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**
**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa	
(Date)	
Signature	
Typed or Printed Name of Person Signing Certificate	

\*This certificate may only be used if paying by deposit account.

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
October 17, 2006	
(Date)	
Signature of Person Mailing Correspondence	
Peter I. Bernstein	
Typed or Printed Name of Person Mailing Certificate	

Dated: October 17, 2006

Peter I. Bernstein  
 Registration No. 43,497  
 Scully, Scott, Murphy & Presser, P.C.  
 400 Garden City Plaza, Suite 300  
 Garden City, New York 11530  
 516-742-4343

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**18467**

In Re Application Of: **Lloyd S. Gray, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
<b>10/589,216</b>	<b>August 11, 2006</b>	<b>Unassigned</b>	<b>23389</b>	<b>Unassigned</b>	<b>Unassigned</b>

Title:

**INHIBITING CAV3 ISOFORMS AND THE  $\delta$  25B SPLICE VARIANTS FOR THE  
DIAGNOSIS AND TREATMENT OF CANCER**

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant(s):</b>	Lloyd S. Gray, et al.	<b>Examiner:</b>	Unassigned
<b>Serial No:</b>	10/589,216	<b>Art Unit:</b>	Unassigned
<b>Filed:</b>	August 11, 2006	<b>Docket:</b>	18467
<b>For:</b>	INHIBITING CAV3 ISOFORMS AND THE $\delta$ 25B SPLICE VARIANTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER	<b>Dated:</b>	October 17, 2006

Mail Stop PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. Merritt J.E. et al., "Regulation of Cytosolic Free Calcium in Fura-2-Loaded Rat Parotid Acinar Cells", *The Journal of Biological Chemistry*, 262(36):17362-17369 (1987);
2. Massie B.M., "Mibefradil: A Selective T-Type Calcium Antagonist", *Am. J. Cardiol*, 80(9A):231-321 (1997);
3. Köhler G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", *Nature*, 256:495-497 (1975);
4. Goding J.W., "Monoclonal Antibodies: Principles and Practice", *N.Y. Academic Press*, pp. 98-119 (1983);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 17, 2006

  
Peter I. Bernstein

5. Colcher D. et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", *Methods in Enzymology*, 121:802-816 (1986);
6. Haverstick D.M. et al., "Increased Intracellular Ca<sup>2+</sup> Induces Ca<sup>2+</sup> Influx in Human T Lymphocytes", *Molecular Biology of the Cell*, 4:173-184 (1993);  
and
7. Haverstick D.M. et al., "Three Intracellular Signals for Cytotoxic T Lymphocyte-Mediated Killing", *The Journal of Immunology*, 146(10):3306-3313 (1991).

The relevance of the above-identified references has been described in the specification. A copy of the foregoing references is enclosed.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

PIB:dg

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		<b>Atty. Docket No. (Optional)</b> 18467	<b>Application Number</b> 10/589,216
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		<b>Applicant(s)</b> Lloyd S. Gray, et al.	
		<b>Filing Date</b> August 11, 2006	<b>Group Art Unit</b> Unassigned
		<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
		Merritt J.E. et al., "Regulation of Cytosolic Free Calcium in Fura-2-Loaded Rat Parotid Acinar Cells", <i>The Journal of Biological Chemistry</i> , 262(36):17362-17369 (1987)	
		Massie B.M., "Mibefradil: A Selective T-Type Calcium Antagonist", <i>Am. J. Cardiol</i> , 80(9A):231-321 (1997)	
		Köhler G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", <i>Nature</i> , 256:495-497 (1975)	
		Goding J.W., "Monoclonal Antibodies: Principles and Practice", <i>N.Y. Academic Press</i> , pp. 98-119 (1983)	
		Colcher D. et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", <i>Methods in Enzymology</i> , 121:802-816 (1986)	
		Haverstick D.M. et al., "Increased Intracellular Ca <sup>2+</sup> Induces Ca <sup>2+</sup> Influx in Human T Lymphocytes", <i>Molecular Biology of the Cell</i> , 4:173-184 (1993)	
		Haverstick D.M. et al., "Three Intracellular Signals for Cytotoxic T Lymphocyte-Mediated Killing", <i>The Journal of Immunology</i> , 146(10):3306-3313 (1991)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			